Clinical Trials Logo

Clinical Trial Summary

Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell lymphoma or leukemia. The CAR consists of a CD19 targeting antibody scFv with three intracellular signaling domains derived from CD3 zeta, CD28 and 4-1BB. Autologous T cells will be gene engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02132624
Study type Interventional
Source Uppsala University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date April 2014
Completion date May 31, 2017

See also
  Status Clinical Trial Phase
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Withdrawn NCT02547948 - CD19-targeting CAR T Cells for B Cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03258047 - Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma Phase 2
Active, not recruiting NCT03478514 - Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Phase 2
Not yet recruiting NCT06058858 - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Recruiting NCT06415708 - Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma Phase 2
Active, not recruiting NCT03307746 - A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma Phase 1/Phase 2
Terminated NCT03670888 - A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients Phase 1
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting NCT06213311 - A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma Phase 2
Recruiting NCT04008251 - Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Phase 1
Recruiting NCT04637763 - CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Phase 1
Recruiting NCT04782193 - a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT03146533 - CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. Phase 1/Phase 2
Recruiting NCT05385263 - Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion Phase 2
Recruiting NCT03366324 - Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies Phase 1/Phase 2
Recruiting NCT03929107 - Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. Phase 2
Enrolling by invitation NCT05332054 - Long-Term Follow-up Study
Recruiting NCT04289220 - Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia Phase 1